Science.Online
Publisher and Institutes
Akademie Verlag
Deutsches Institut für Urbanistik
Oldenbourg Wissenschaftsverlag
Walter de Gruyter
Schattauer
You are here: Home :: Area NEM :: Medical science :: Human medicine
 
Martine Vercammen, Patricia Meirlaen, Jacques Sennesael, Brigitte Velkeniers, Sara T'Kint, Leon Verbruggen, Patrick Haentjens, Linda Broodtaerts, Christian Demanet, Marc De Waele

Diagnostic accuracy of the FIDIS multiplex fluorescent microsphere immunodetection system for anti-extractable nuclear antigen (ENA) antibodies in connective tissue diseases

Keywords: anti-extractable nuclear antigen antibodies, antinuclear antibodies, autoimmunity, connective tissue diseases, immunoassays, Luminex, multiplex

Background: Anti-extractable nuclear antigen antibodies (ENA) are markers of connective tissue diseases (CTDs).

Methods: We compared FIDIS reagents in the multiplex fluorescent microsphere immunodetection system to INNO-LIA and immunodiffusion for 174 antinuclear antibody-positive patients, 102 with well-defined CTDs and 72 disease controls.

Results: No significant differences were found in sensitivity or specificity between FIDIS and immunodiffusion, or between FIDIS and INNO-LIA for all anti-ENA in all CTD patients; nor were any differences found for individual anti-ENAs within distinct CTDs. The FIDIS sensitivity was 41% (anti-SSA) and 17% (anti-SSB) in lupus erythematosus (LE) or primary Sjögren's syndrome; 5% (anti-ribosome and anti-Sm) in LE; 17% (anti-RNP) in LE or mixed CTD; 21% (anti-Scl70) in systemic sclerosis; and 61% (anti-centromere) in limited systemic sclerosis. The specificity reached 88%–100%. Receiver operating characteristic curve areas did not differ between FIDIS and INNO-LIA. Agreement ranged from 91% (anti-SSB) to 99% (anti-Jo1) between FIDIS and INNO-LIA, and from 95% (anti-Scl70) to 100% (anti-Sm) between FIDIS and immunodiffusion. Samples scored positive with all techniques in 83% (anti-centromere), 70% (anti-RNP), 67% (anti-Jo1), 60% (anti-SSA), 40% (anti-SSB), 33% (anti-ribosome), 25% (anti-Sm) and 13% (anti-Scl70) of cases.

Conclusions: The diagnostic performance of FIDIS anti-ENA reagents is comparable to immunodiffusion and INNO-LIA.

Clin Chem Lab Med 2007;45:505–12.

Clinical Chemical Laboratory Medicine, Walter de Gruyter

Print ISSN: 1434-6621
Volume: 45, 04/2007
Pages: 505 - 512

Show full article (external site)

Show all available items of this journal